Appendix 11.5c Myocarditis/Pericarditis Patients less than 18 of age after Dose 2 and Dose 3-Case listings 669
Appendix 11.5d Myocarditis/Pericarditis Patients less than 18 of age after Dose 2 and Dose 3-Case narratives 670
Appendix 11.5e Myocarditis-Pericarditis Fatal reports Case Listings 671
Appendix 11.5f Myocarditis-Pericarditis Fatal reports Case Narratives 672
Appendix 11.5g Myocarditis: Literature search Methodology 673
Appendix 11.6a Pregnancy: Distribution of Case and Event Counts by
SOC/HLT/PT Stratified by Event seriousness for Interval and Cumulative 675
Appendix 11.6b Pregnancy: Summary of pregnancy outcomes by trimester of exposure, and retrospective/prospective case classification, Reporting Period 676
Appendix 11.6c Pregnancy: Summary of pregnancy outcomes by trimester of exposure, and retrospective/prospective case classification, Cumulative 677
Appendix 11.6d Pregnancy: Sun nary of reported congenital anomalies by HLT and PT that occurred in fetuses and neonates, Cumulative 678
Appendix 11.6e Pregnancy: Distribution of Case and Event Counts by SOC/HLT/PT Stratified by Event Seriousness for Adolescents, Interval and Cumulative 679
Appendix 11.6f Pregnancy: Targeted Literature Search Strategy for Pregnancy and Lactation for The Reporting Period (01 Jan 2022-18 Jun 2022 680
Appendix 11.7 Lactation-related Cases Under 5 years of Age with Serious Lactation-related events, Cumulative 681
Appendix 11.8 Use in immunocompromised subjects: Literature search methodology 682
Appendix 11.9a Interaction with Other COVID-19 vaccines (Heterologous Vaccine Schedule): Literature search 683
Appendix 11.9b Interaction with Other COVID-19 vaccines (Heterologous Vaccine Schedule): Various Synonyms terms of SPIKEVAX 684
Appendix 11.9c Interaction with Other COVID-19 vaccines (Heterologous Vaccine Schedule): Articles/Abstracts Appendix 11.9c Interaction with Other COVID-19 vaccines (Heterologous Vaccine Schedule): Articles/Abstracts 685
Appendix 11.9d Interaction with Other COVID-19 vaccines (Heterologous Vaccine Schedule): Fatal cases: Case Listings and Case Narratives) 686
Documents with Appendices 5.c-11.9d available here (pp.1569-1868) and prolonged Appendix 11.9 from pp. 1868-2050 available here (pp. 1869-2268)
Appendix 11.9e Interaction: with Other COVID-19 vaccines (Heterologous Vaccine Schedule): Immunocompromised co-morbidities Dose 3 & 4 688
Documents with Appendix 11.9e available here 2269-2734 and prolonged pp. 2735- 2862 available here (pp. 2735-3034)
Appendix 11.9f Interaction: with Other COVID-19 vaccines (Heterologous Vaccine Schedule): Immunocompromised co-morbidities Dose 3 & 4
Appendix 11.10 Narratives-RP Use in frail subjects: Fatal cases: Case Listings and Case 689
Document with Appendices 11.9f -11.10 available here (pp. 2735-3034)
Appendix 11.11a Use in Patients with Autoimmune or Inflammatory Disorders:
Literature Search Methodology
Appendix 11.11b Use in patients with Autoimmune or Inflammatory Disorders:
Fatal cases: Case Listings and Case Narratives
Appendix 11.11c Use in Patients with Autoimmune or Inflammatory Disorders: PTs of Autoimmune/Inflammatory Disorder (AI/M) SMQ in Reports with Past MIHX of AI/ID, representing a subset of potential flares (Cumulative)
Appendix 11.12a Myasthenia gravis: New Onset MG-Case Listings
Appendix 11.12b Myasthenia gravis: New Onset MG-Case Narratives
Appendix 11.12c Myasthenia gravis: MG flare-Case Listings
Appendix 11.12d Myasthenia gravis: MG flare-Case Narratives
Appendix 11.12e Myasthenia gravis: Literature Search Methodology
Appendix 11.13a Use in Patients with Autoimmune c• Irlammatory Disorders
(Autoimmune Hemolytic Anemia): Cumulative Evaluation-Case listings
Appendix 11.13b Use in Patients with Autoimmune or Inflammatory Disorders
(Autoimmune Hemolytic Anemia): Cumulative Evaluation-Case Narratives
Document with Appendices 11.11a-11.13b available here (pp. 3035-3417)
(*3418-3764)